Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2015

Schedule Of Cost And Fair Value Of Marketable Securities


		September 30, 2015
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Certificates of Deposit	$	6,480,000	$	6,869	$	-	$	6,486,869
Corporate Bonds		2,519,900		282		(382)		2,519,800
Total Marketable Securities	$	8,999,900	$	7,151	$	(382)	$	9,006,669

		December 31, 2014
		Cost		Gross Unrealized		Gross Unrealized		Fair
		Basis		Gains		Losses		Value
Certificates of Deposit	$	18,865,000	$	60	$	(26,789)	$	18,838,271
Commercial Paper		1,998,001		62		(153)		1,997,910
Corporate Bonds		2,042,697		-		(6,827)		2,035,870
Total Marketable Securities	$	22,905,698	$	122	$	(33,769)	$	22,872,051

Schedule Of Cost And Fair Value By Contractual Maturity


Maturity	Cost Basis		Fair Value
Less than 1 year	$	8,519,900	$	8,525,822
1 to 5 years		480,000		480,847
Total Marketable Securities	$	8,999,900	$	9,006,669

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details